Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 20552377)

  • 1. Enhancing adherence to capecitabine chemotherapy by means of multidisciplinary pharmaceutical care.
    Simons S; Ringsdorf S; Braun M; Mey UJ; Schwindt PF; Ko YD; Schmidt-Wolf I; Kuhn W; Jaehde U
    Support Care Cancer; 2011 Jul; 19(7):1009-18. PubMed ID: 20552377
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Capecitabine non-adherence: exploration of magnitude, nature and contributing factors.
    Bhattacharya D; Easthall C; Willoughby KA; Small M; Watson S
    J Oncol Pharm Pract; 2012 Sep; 18(3):333-42. PubMed ID: 22298660
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Study on adherence to capecitabine among patients with colorectal cancer and metastatic breast cancer.
    Figueiredo Junior AG; Forones NM
    Arq Gastroenterol; 2014; 51(3):186-91. PubMed ID: 25296077
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Over-adherence to capecitabine: a potential safety issue in breast and colorectal cancer patients.
    Le Saux O; Bourmaud A; Rioufol C; Colomban O; Guitton J; Schwiertz V; Regnier V; You B; Ranchon F; Maraval-Gaget R; Girard P; Chauvin F; Freyer G; Tod M; Henin E; Trillet-Lenoir V
    Cancer Chemother Pharmacol; 2018 Aug; 82(2):319-327. PubMed ID: 29948022
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adherence to capecitabine treatment and contributing factors among cancer patients in Malaysia.
    Zahrina AK; Norsa'adah B; Hassan NB; Norazwany Y; Norhayati I; Roslan MH; Wan Nazuha WR
    Asian Pac J Cancer Prev; 2014; 15(21):9225-32. PubMed ID: 25422205
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacology and therapeutic efficacy of capecitabine: focus on breast and colorectal cancer.
    Aprile G; Mazzer M; Moroso S; Puglisi F
    Anticancer Drugs; 2009 Apr; 20(4):217-29. PubMed ID: 19247178
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Capecitabine in the treatment of colorectal cancer.
    Kelly C; Cassidy J
    Expert Rev Anticancer Ther; 2007 Jun; 7(6):803-10. PubMed ID: 17555390
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Thymidine phosphorylase expression and benefit from capecitabine in patients with advanced breast cancer.
    Andreetta C; Puppin C; Minisini A; Valent F; Pegolo E; Damante G; Di Loreto C; Pizzolitto S; Pandolfi M; Fasola G; Piga A; Puglisi F
    Ann Oncol; 2009 Feb; 20(2):265-71. PubMed ID: 18765464
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Significant association between hand-foot syndrome and efficacy of capecitabine in patients with metastatic breast cancer.
    Azuma Y; Hata K; Sai K; Udagawa R; Hirakawa A; Tohkin M; Ryushima Y; Makino Y; Yokote N; Morikawa N; Fujiwara Y; Saito Y; Yamamoto H
    Biol Pharm Bull; 2012; 35(5):717-24. PubMed ID: 22687407
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adjuvant chemotherapy in older women with early-stage breast cancer.
    Muss HB; Berry DA; Cirrincione CT; Theodoulou M; Mauer AM; Kornblith AB; Partridge AH; Dressler LG; Cohen HJ; Becker HP; Kartcheske PA; Wheeler JD; Perez EA; Wolff AC; Gralow JR; Burstein HJ; Mahmood AA; Magrinat G; Parker BA; Hart RD; Grenier D; Norton L; Hudis CA; Winer EP;
    N Engl J Med; 2009 May; 360(20):2055-65. PubMed ID: 19439741
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Capecitabine in colorectal carcinoma: news from ASCO 2008]].
    Longo F; Mansueto G
    Tumori; 2008; 94(4):suppl 15-23. PubMed ID: 18822712
    [No Abstract]   [Full Text] [Related]  

  • 12. Capecitabine in colorectal, breast, and other solid tumors: novel therapeutic approaches. Selected abstracts from ASCO 2003.
    Oncology (Williston Park); 2003 Aug; 17(8 Suppl 8):10-62; quiz 63-4. PubMed ID: 14570064
    [No Abstract]   [Full Text] [Related]  

  • 13. Costs associated with capecitabine or 5-fluorouracil monotherapy after surgical resection in patients with colorectal cancer.
    Chu E; Shi N; Wei W; Bendell JC; Cartwright T
    Oncology; 2009; 77(3-4):244-53. PubMed ID: 19738390
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Implementation of capecitabine (Xeloda) into a cancer centre: UK experience.
    Faithfull S; Deery P
    Eur J Oncol Nurs; 2004; 8 Suppl 1():S54-62. PubMed ID: 15341882
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Capecitabine versus classical cyclophosphamide, methotrexate, and fluorouracil as first-line chemotherapy for advanced breast cancer.
    Stockler MR; Harvey VJ; Francis PA; Byrne MJ; Ackland SP; Fitzharris B; Van Hazel G; Wilcken NR; Grimison PS; Nowak AK; Gainford MC; Fong A; Paksec L; Sourjina T; Zannino D; Gebski V; Simes RJ; Forbes JF; Coates AS
    J Clin Oncol; 2011 Dec; 29(34):4498-504. PubMed ID: 22025143
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Self-reported compliance with capecitabine: findings from a prospective cohort analysis.
    Winterhalder R; Hoesli P; Delmore G; Pederiva S; Bressoud A; Hermann F; von Moos R;
    Oncology; 2011; 80(1-2):29-33. PubMed ID: 21606661
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adherence with oral oncologic treatment in cancer patients: interest of an adherence score of all dosing errors.
    Thivat E; Van Praagh I; Belliere A; Mouret-Reynier MA; Kwiatkowski F; Durando X; Mahammedi H; Dillies AF; Chollet P; Chevrier R
    Oncology; 2013; 84(2):67-74. PubMed ID: 23128040
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Capecitabine, alone and in combination, in the management of patients with colorectal cancer: a review of the evidence.
    Comella P; Casaretti R; Sandomenico C; Avallone A; Franco L
    Drugs; 2008; 68(7):949-61. PubMed ID: 18457461
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Economic evaluation of capecitabine as adjuvant or metastatic therapy in colorectal cancer.
    Best JH; Garrison LP
    Expert Rev Pharmacoecon Outcomes Res; 2010 Apr; 10(2):103-14. PubMed ID: 20384557
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Quality of life under capecitabine (Xeloda®) in patients with metastatic breast cancer: data from a german non-interventional surveillance study.
    Müller V; Fuxius S; Steffens CC; Lerchenmüller C; Luhn B; Vehling-Kaiser U; Hurst U; Hahn LJ; Soeling U; Wohlfarth T; Zaiss M
    Oncol Res Treat; 2014; 37(12):748-55. PubMed ID: 25531721
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.